ATM deficiency confers specific therapeutic vulnerabilities in bladder cancer by Yuzhen Zhou et al from Kent Mouw team. doi.org/10.1126/sciadv…

Huge congrats to talented first author Yuzhen Zhou and co-authors Elio Adib Sophia Kamran, MD Konrad Stawiski MD PhD Amin Nassar, MD Raie Bekele Phillip Abbosh David Miyamoto MD PhD and others. Finally thanks to Science Advances for a thorough and efficient publication experience!...11/end.

Congrats, Filipe! Filipe LF Carvalho

Happy to share this latest work from our lab online now European Urology! authors.elsevier.com/a/1iov514kplyy… We report exciting activity of EV and SG in combination with radiation in preclinical bladder cancer models. Led by Yuzhen Zhou with help from Filipe LF Carvalho joaquim bellmunt et al.

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer by Yuzhen Zhou Kent Mouw team. doi.org/10.1016/j.euru…

⚡️Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer #BladderCancer joaquim bellmunt Filipe LF Carvalho Will Anderson Kent Mouw European Urology europeanurology.com/article/S0302-…

Thank you for featuring our work! Yuzhen Zhou Vince D’Andrea, MD Raie Bekele Filipe LF Carvalho joaquim bellmunt Brigham and Women’s Radiation Oncology Dana-Farber Lank Center for Genitourinary Oncology

“In the preclinical space, we continue to be interested in trying to understand the mechanistic underpinnings of these combination therapies,” says Dr. Kent W. Mouw on ADC combinations in bladder cancer. Kent Mouw Dana-Farber Lank Center for Genitourinary Oncology #blcsm Watch now: urologytimes.com/view/dr-mouw-o…

IBCN 2024 REMINDER: The deadline for abstract submission is rapidly approaching! Abstracts must be submitted by May 31st. ibcnweb.com/abstracts/ Roland Seiler-Blarer Peter Black Tilman Todenhöfer Kent Mouw Lars Dyrskjøt @JeffreyD_UNC

In Urology Times: In this video, Kent Mouw discusses the implications and potential future work based on the publication, “Activity of enfortumab vedotin and sacituzumab govitecan with radiation in preclinical models of bladder cancer. Click to watch: urologytimes.com/view/dr-mouw-o…

Congrats to Elizabeth (MD) and Surish (MS) on their upcoming graduations! Thanks for all of your contributions in lab and we are excited for the next phases of your career! Surish Shanmugam, MBChB, MSc, RCPUK (Med Oncology) Raie Bekele Yuzhen Zhou Brigham and Women’s Radiation Oncology Dana-Farber

⚡️ Out on European Urology - Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer #BladderCancer Kent Mouw joaquim bellmunt Will Anderson europeanurology.com/article/S0302-…

Preclinical study evaluates enfortumab vedotin and sacituzumab govitecan with radiation for #BladderCancer. Kent Mouw Dana-Farber and Leslie Ballas Cedars-Sinai discuss preclinical effects of combining EV and sacituzumab govitecan with radiation > bit.ly/4cfLyNc

Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer by Yuzhen Zhou Full article: buff.ly/45RiXvk Vince D’Andrea, MD Raie Bekele joaquim bellmunt Kent Mouw #Medtwitter #UroSoMe #BladderCancer

Thank you for highlighting our work! We hope this provides support for integrating these ADCs into bladder-sparing treatment approaches for MIBC. Brigham and Women’s Radiation Oncology Dana-Farber Lank Center for Genitourinary Oncology Rebecca Johnson IBCN IBCG

Preclinical study evaluates enfortumab vedotin and sacituzumab govitecan with radiation for #BladderCancer. Kent Mouw Dana-Farber and Leslie Ballas Cedars-Sinai discuss preclinical effects of combining EV and sacituzumab govitecan with radiation > bit.ly/4cfLyNc

Excited to be in San Diego and learn about the latest advances in bladder cancer research and care! #BCANTT24 #BladderCancer

It was awesome to meet you Raie Bekele good luck in your job hunting! You will do great! Bladder Cancer Advocacy Network #BCANTT24

Excited to see friends and colleagues in Houston for #IBCG2024. Great morning session on current and emerging therapy approaches for MIBC! IBCG

Congrats Filipe LF Carvalho! Very well deserved!